Eikon Therapeutics (EIKN) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$88.4M

Net income growth (year over year)

+15.97%

Net margin

—

Return on equity

—

EPS (trailing twelve months)

−$54.11

Book value per share

$8.62

P/E (trailing twelve months)

—

Price to book

0.81

Debt to assets

40.16%

Payout ratio

—

Dividend yield

—

Company profile

Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.

• How do I buy stock in Eikon Therapeutics (EIKN)?

  EIKN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.